GlassScriptPhysician profile
Mary Mcmillin
NPI 1912296047
$2,960.06
in general payments reported to CMS, 2019-2025
46 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $408 · 2023: $605 · 2024: $551 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,346 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.93 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $220.14 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $214.69 | 2022-2025 | |
| Incyte Corporation | $191.78 | 2021-2025 | Monjuvi, Zynyz, Jakafi |
| Merck Sharp & Dohme LLC | $169.74 | 2021-2025 | Keytruda, Lynparza, Reblozyl |
| Janssen Biotech, INC. | $167.46 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| Astellas Pharma US INC | $145.59 | 2023-2025 | Xtandi, Vyloy |
| Eisai INC. | $129.68 | 2021-2025 | |
| Lilly USA, LLC | $122.06 | 2022-2025 | Verzenio, Jaypirca |
| Aveo Pharmaceuticals, INC. | $118.13 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $100.28 | 2021-2025 | Imfinzi, Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $93.43 | 2021-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $84.60 | 2024-2025 | Opdivo |
| Genzyme Corporation | $81.28 | 2023-2025 | |
| Celgene Corporation | $81.23 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Novartis Pharmaceuticals Corporation | $69.99 | 2022-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $68.78 | 2023-2025 | Epkinly |
| Abbvie INC. | $67.91 | 2023-2025 | |
| Amgen INC. | $59.29 | 2021-2023 | Lumakras |
| Exelixis INC. | $49.99 | 2022-2025 | Cabometyx |
| Tempus Ai, INC | $46.57 | 2024-2025 | Xt Cdx |
| Gilead Sciences, INC. | $44.79 | 2022-2025 | Trodelvy |
| Springworks Therapeutics, INC. | $43.19 | 2025 | Gomekli |
| Takeda Pharmaceuticals U.S.A., INC. | $42.26 | 2023-2025 | Ninlaro |
| Glaxosmithkline, LLC. | $39.71 | 2024 | Ojjaara |
| Beigene USA, INC. | $38.51 | 2022-2025 | Tevimbra, Brukinsa |
| Seagen INC. | $36.57 | 2022-2023 | Adcetris |
| Servier Pharmaceuticals LLC | $36.29 | 2022-2025 | |
| Stemline Therapeutics INC. | $36.18 | 2023-2025 | Orserdu |
| Taiho Oncology, INC. | $29.84 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $28.02 | 2023-2024 | Pyrukynd |
| Sobi, INC | $24.23 | 2025 | |
| Beone Medicines USA, INC. | $24.14 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $22.82 | 2024 | |
| Karyopharm Therapeutics INC. | $22.77 | 2025 | Xpovio |
| Kyowa Kirin, INC. | $21.25 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.25 | 2024 | Ultomiris |
| Tersera Therapeutics LLC | $18.95 | 2025 | Zoladex |
| Genentech USA, INC. | $18.47 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.06 | 2023 | Qinlock |
| Geron Corporation | $17.40 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $17.17 | 2025 | Sylvant |
| Pharmacosmos Therapeutics INC. | $17.00 | 2025 | Monoferric |
| Puma Biotechnology, INC. | $16.86 | 2025 | |
| Cti Biopharma Corp. | $15.57 | 2023 | Vonjo |
| Novocure INC. | $14.63 | 2025 | Optune Lua (Novottf-200t) |
| Janssen Pharmaceuticals, INC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mcmillin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.